WALVAX BIOTECHNOLOGY CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.33 CNY | +3.54% |
|
+2.43% | -39.05% |
| Apr. 26 | Walvax Biotechnology's Profit Drops 92%, Operating Income Slids 28% in Q1 2024 | MT |
| Apr. 25 | Walvax Biotechnology's Unit to End COVID-19 Vaccine Trial | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 49,874 | 59,516 | 89,423 | 64,274 | 37,601 | 22,919 | - | - |
| Enterprise Value (EV) 1 | 49,874 | 59,516 | 86,294 | 60,835 | 34,022 | 18,749 | 18,152 | 17,304 |
| P/E ratio | 351 x | 59.9 x | 207 x | 88.4 x | 89.7 x | 29.2 x | 20.6 x | 18.4 x |
| Yield | - | 0.13% | 0.05% | 0.02% | 0.04% | 0.7% | 0.84% | 1.12% |
| Capitalization / Revenue | 44.5 x | 20.3 x | 25.8 x | 12.6 x | 9.14 x | 5.55 x | 4.27 x | 4.01 x |
| EV / Revenue | 44.5 x | 20.3 x | 24.9 x | 12 x | 8.27 x | 4.54 x | 3.38 x | 3.03 x |
| EV / EBITDA | - | 39.6 x | 101 x | 44.8 x | 37 x | 12.4 x | 10.7 x | 8.14 x |
| EV / FCF | -172,214,470 x | - | - | - | - | - | - | - |
| FCF Yield | -0% | - | - | - | - | - | - | - |
| Price to Book | 10.3 x | 9.11 x | - | - | 4.04 x | 2.1 x | 1.89 x | - |
| Nbr of stocks (in thousands) | 1,537,437 | 1,543,452 | 1,591,158 | 1,599,253 | 1,599,349 | 1,599,349 | - | - |
| Reference price 2 | 32.44 | 38.56 | 56.20 | 40.19 | 23.51 | 14.33 | 14.33 | 14.33 |
| Announcement Date | 2/6/20 | 3/25/21 | 3/18/22 | 3/29/23 | 3/29/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 1,121 | 2,939 | 3,463 | 5,086 | 4,114 | 4,132 | 5,365 | 5,717 |
| EBITDA 1 | - | 1,505 | 851.4 | 1,358 | 920 | 1,517 | 1,689 | 2,125 |
| EBIT 1 | 232.9 | 1,376 | 710.3 | 1,099 | 614 | 1,203 | 1,687 | 1,850 |
| Operating Margin | 20.77% | 46.83% | 20.51% | 21.62% | 14.92% | 29.1% | 31.45% | 32.37% |
| Earnings before Tax (EBT) 1 | 229.5 | 1,373 | 708.9 | - | 599 | 1,642 | 1,857 | - |
| Net income 1 | 142 | 1,003 | 427.7 | 728.7 | 419.4 | 781.2 | 1,121 | 1,261 |
| Net margin | 12.66% | 34.13% | 12.35% | 14.33% | 10.19% | 18.9% | 20.89% | 22.06% |
| EPS 2 | 0.0923 | 0.6434 | 0.2719 | 0.4544 | 0.2621 | 0.4900 | 0.6950 | 0.7800 |
| Free Cash Flow | -289.6 | - | - | - | - | - | - | - |
| FCF margin | -25.83% | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | 0.0500 | 0.0270 | 0.0100 | 0.0100 | 0.1000 | 0.1200 | 0.1600 |
| Announcement Date | 2/6/20 | 3/25/21 | 3/18/22 | 3/29/23 | 3/29/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 1,334 | 655.9 | 1,692 | 1,358 | 1,380 | 833.3 | 1,334 | 990.4 | 955.7 | 599.8 | 1,466 | 1,033 | 1,033 | 729.4 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | 146.7 | 92.73 | 523.4 | 212.9 | 270.4 | 214.5 | 417.6 | 147.3 | -165.3 | 59.65 | 512.8 | 302 | 265.1 | 104.3 |
| Operating Margin | 11% | 14.14% | 30.93% | 15.68% | 19.59% | 25.74% | 31.29% | 14.87% | -17.3% | 9.95% | 34.97% | 29.23% | 25.66% | 14.29% |
| Earnings before Tax (EBT) | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net income | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | - | 0.0241 | 0.2379 | 0.0800 | 0.1100 | 0.1074 | 0.1700 | 0.0613 | -0.0900 | 0.008800 | 0.2500 | 0.1100 | 0.1200 | 0.0300 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/18/22 | 4/28/22 | 8/10/22 | 10/24/22 | 3/29/23 | 4/24/23 | 8/25/23 | 10/25/23 | 3/29/24 | 4/24/24 | - | - | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | - | - | 3,129 | 3,439 | 3,579 | 4,169 | 4,766 | 5,615 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow | -290 | - | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | 3.01% | 18.1% | - | - | 4.54% | 9.7% | 10.2% | - |
| ROA (Net income/ Total Assets) | - | 12% | - | - | - | 6.1% | 6.4% | - |
| Assets 1 | - | 8,328 | - | - | - | 12,806 | 17,515 | - |
| Book Value Per Share 2 | 3.160 | 4.230 | - | - | 5.820 | 6.840 | 7.570 | - |
| Cash Flow per Share | - | 0.0700 | - | - | - | - | - | - |
| Capex 1 | 352 | 403 | 1,100 | - | 945 | 54 | 59 | - |
| Capex / Sales | 31.36% | 13.7% | 31.76% | - | 22.97% | 1.31% | 1.1% | - |
| Announcement Date | 2/6/20 | 3/25/21 | 3/18/22 | 3/29/23 | 3/29/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
HOLD
Number of Analysts
2
Last Close Price
14.33
CNY
Average target price
20
CNY
Spread / Average Target
+39.57%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -39.05% | 3.16B | |
| -4.66% | 86.13B | |
| +1.32% | 39.82B | |
| -19.27% | 30.42B | |
| +57.86% | 25.23B | |
| -17.69% | 11.6B | |
| -43.00% | 11.51B | |
| -9.14% | 11.95B | |
| +5.24% | 8.71B | |
| -8.42% | 8.12B |
- Stock Market
- Equities
- 300142 Stock
- Financials Walvax Biotechnology Co., Ltd.
